The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.
ESC 2018 The PURE cohort study showed reduced risk of CV disease and mortality with high-quality diets in general populations worldwide.
EPCCS 2018 Three professors discuss how best to measure blood pressure, when to call it hypertension, and once hypertension is diagnosed, what BP target to aim for, based on the latest scientific insights.
This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
ADA 2018 In long-term Danish Steno 2 study, interventions targeting complications were found to improve disease-free-life length, and costs were not higher than with conventional treatment.
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension
No consistent benefit was seen of popular supplements (multivitamins, vitamin D, calcium and vitamin C) for the prevention of CVD, myocardial infarction or stroke, or on all-cause mortality.
EPCCS 2018 A recording of the lecture by Prof. Visseren, on practical issues of managing elevated lipids and statins: why do many patients not take their medication, and how can we improve this?
Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.
A multidisciplinary ESC Task Force aimed to give as much practical advice as possible on the most appropriate management and therapy for each of the subtypes of syncope, although trial evidence is scarce.